🔴A strong case for a long-hanging question!
A monumental #DrugDiscovery #perspective on #JMedChem.
Well done @arash4sadri 👏
https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01737?ref=pdf
#Nucleoside #chemistry is where I started more than 20 years ago as a young MedChem student in the group of Maurizio Botta.
A back to the future adventure has brought us today to this new paper on #ChemMedChem.
We have tried to teach these old dogs new tricks for the development of #broadspectrum #antimicrobial agents.
#MedChem #DrugDiscovery #Antiviral
https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202300200
Happy to share our just accepted #review on #multitarget approaches for the #synthesis of #purine and #pyrimidine derivatives. From the #prebiotic/#abiotic origin of life to new #green #chemistry strategies for #drugdiscovery.
https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/ejoc.202201288?utm_source=google&utm_medium=paidsearch&utm_campaign=R3MR425&utm_content=Chemistry
An interesting point on #drugdiscovery
“.... How do we truly define a #smallmolecule #drug today? ... Are #chemists making the “wrong” kinds of molecules?
Or have we entered a new era of drug modalities?
.... And just to prove chemists can continue to make the “right” kinds of molecules, here are some recent low Mw drug #approvals -
- Tecfidera (Mw 144), #FDA approved 2013
- Tavaborole (Mw 151), FDA approved 2014
- Avibactam (Mw 265), FDA approved 2015
- Benznidazole (Mw 260), FDA approved 2017
- Migalastat (Mw 163), FDA approved 2018
How many novel small molecule drugs Mw<300 are yet to be discovered?”
As additional Appendix to my #introduction, I would like to #boost our recent #DrugDiscovery efforts in the field of #CysticFibrosis: we have developed #MultiTarget compounds acting at the same time as #CFTR #Correctors and #Antibacterials or #Antivirals depending on the specific functionalization of the same chemotype.
https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202200277
https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01416
As second Appendix to my #introduction, I would like to #boost our recent #DrugDiscovery efforts in the development of #BroadSpectrum #Antivirals.
#SarsCov2 #ZIKV #Rhinovirus #enterovirus
https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202100483
As appendix to my #Introduction and catalyst for possible collaborations in the field, I would like to #boost our recent #DrugDiscovery effort in the modulation of the #CCL20/#CCR6 axis to identify new #inhibitors for #IBD and other #diseases depending on the same axis.
https://www.sciencedirect.com/science/article/abs/pii/S0223523422006055
-Time for a short #Introduction-
I am a group leader in #MedicinalChemistry at the University of Parma. My lab combines #chemical & #computational techniques to develop novel pharmacological tools to study different Chronic Diseases (#CysticFibrosis, #IBD, #Hypercholesterolemia, #Alzheimer, #Cancer) and Infective Agents (#SARSCoV2, #Enterovirus, #Flavivirus, #Monkeypox, #HIV).
We are particularly interested in the development of #MultiTarget inhibitors and open to new #collaborations in #DrugDiscovery.
#Tooting (sooner or later) about the #chemistry and #science
Professor of Medicinal Chemistry at the University of Parma (Italy).
Developing novel drug candidates for Chronic and Infective Diseases.
Interests:
#MedChem #MedicinalChemistry #DrugDiscovery #Chemistry #MultiTarget #Antiviral #Antibacterial #Anticancer #IBD #CVD #Alzheimer #CysticFibrosis #Medicine #Pharmacology #Biotech #ccr6 #pcsk9 #bsaa